title: Levomilnacipran for the treatment of major depressive disorder: a review.
abstract: Levomilnacipran (LVM, Fetzima(®)) was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder. It is a unique dual neurotransmitter reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, including duloxetine, venlafaxine, and desvenlafaxine, it has greater selectivity for inhibiting norepinephrine reuptake than serotonin reuptake. Our review focuses on the efficacy, safety, and tolerability data for five double-blind, placebo-controlled, short-term studies and two long-term studies. In the short-term studies, LVM was found to be more effective than placebo in reducing depression (Montgomery-Åsberg Depression Rating Scale) scores as well as improving functional impairment (Sheehan Disability Scale) scores. Long-term studies found LVM to be similarly effective but in the only placebo-controlled long-term study, LVM was not significantly superior to placebo. LVM is fairly well tolerated, with the most common adverse events being nausea, headache, dry mouth, hyperhidrosis, and constipation. Discontinuation rates were mildly increased in those being treated with LVM (9%) versus placebo (3%). Adverse events were not dose-related except for urinary hesitancy and erectile dysfunction. LVM was weight neutral, was not toxic to the liver, and did not cause clinically significant QTc prolongation. Consistent with being a predominant potentiator of norepinephrine, pulse and blood pressure were significantly elevated by LVM but rarely induced tachycardia or hypertension. LVM is a relatively safe alternative antidepressant treatment with minimal drug-drug interactions. It is the only antidepressant that has in its labeling that it is not only effective in improving depression but also effective in improving impaired functioning. Whether this important effect on functioning is unique to LVM must be researched. In addition, whether LVM might be effective in norepinephrine-deficit depression, refractory depression, atypical depression, or seasonal depression is yet to be evaluated. Ultimately, head-to-head studies comparing LVM with other antidepressants will determine the place of LM in antidepressant treatment.
authors: Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, New York, NY, USA ; Anxiety and Depression Clinic, Montefiore Medical Center, Bronx, New York, NY, USA.
authors: Gregory M
authors: GM
authors: Asnis
authors: Anxiety and Depression Clinic, Montefiore Medical Center, Bronx, New York, NY, USA.
authors: Margaret A
authors: MA
authors: Henderson
keywords: antidepressant; clinical efficacy; functional impairment; levomilnacipran
references: Am J Psychiatry. 2000 Sep;157(9):1445-52
references: 10964861
references: Int Clin Psychopharmacol. 2001 Nov;16(6):353-5
references: 11712624
references: Eur Neuropsychopharmacol. 2002 Apr;12(2):119-22
references: 11872327
references: JAMA. 2003 Jun 18;289(23):3095-105
references: 12813115
references: Acta Psychiatr Scand. 2004 Sep;110(3):208-14
references: 15283741
references: Compr Psychiatry. 2004 Nov-Dec;45(6):423-30
references: 15526252
references: Eur Heart J. 2005 Oct;26(19):2007-12
references: 15888497
references: J Psychiatr Res. 2007 Apr-Jun;41(3-4):351-9
references: 16165158
references: Am J Psychiatry. 2006 Jan;163(1):28-40
references: 16390886
references: Arch Gen Psychiatry. 2006 Mar;63(3):332-9
references: 16520440
references: J Pharmacol Exp Ther. 2006 Aug;318(2):657-65
references: 16675639
references: Int J Neuropsychopharmacol. 2007 Feb;10(1):41-50
references: 16690005
references: Am Fam Physician. 2006 Aug 1;74(3):449-56
references: 16913164
references: Am J Psychiatry. 2006 Nov;163(11):1905-17
references: 17074942
references: J Clin Psychiatry. 2008;69 Suppl E1:4-7
references: 18494537
references: Am J Geriatr Psychiatry. 2008 Jul;16(7):558-67
references: 18591576
references: J Psychiatr Res. 2009 Feb;43(5):503-11
references: 18752809
references: Eur Neuropsychopharmacol. 2009 Jan;19(1):34-40
references: 18823760
references: J Clin Psychopharmacol. 2009 Feb;29(1):9-15
references: 19142100
references: Int Clin Psychopharmacol. 2009 May;24(3):111-8
references: 19357527
references: Psychol Med. 2010 Jan;40(1):41-50
references: 19460188
references: BMJ. 2009 Aug 11;339:b2880
references: 19671933
references: J Clin Psychopharmacol. 2010 Oct;30(5):641
references: 20841968
references: Int Clin Psychopharmacol. 2011 Mar;26(2):75-83
references: 21102344
references: J Clin Psychiatry. 2011 Apr;72(4):464-72
references: 21527123
references: Neuropsychiatr Dis Treat. 2011;7(Suppl 1):9-13
references: 21750623
references: Am J Psychiatry. 2011 Dec;168(12):1266-77
references: 22193671
references: Neuropharmacology. 2013 Jul;70:338-47
references: 23499664
references: J Clin Psychiatry. 2013 Mar;74(3):242-8
references: 23561229
references: J Clin Psychiatry. 2013 Apr;74(4):363-9
references: 23656841
references: Int Clin Psychopharmacol. 2013 Nov;28(6):312-21
references: 23881185
references: Clin Drug Investig. 2013 Oct;33(10):761-71
references: 23999912
references: Int J Clin Pract. 2013 Nov;67(11):1089-104
references: 24016209
references: J Psychiatry Neurosci. 2014 Jan;39(1):40-9
references: 24144196
references: Int Clin Psychopharmacol. 2014 Jan;29(1):26-35
references: 24172160
references: J Clin Psychopharmacol. 2014 Feb;34(1):47-56
references: 24172209
references: Expert Rev Clin Pharmacol. 2014 Mar;7(2):137-45
references: 24524592
references: Innov Clin Neurosci. 2014 Jan;11(1-2):10-22
references: 24653937
references: Int Clin Psychopharmacol. 2014 Jul;29(4):197-205
references: 24667487
references: Curr Ther Res Clin Exp. 2005 Mar;66(2):96-106
references: 24672116
references: Gastroenterology. 2014 Jul;147(1):20-4
references: 24880009
references: CNS Spectr. 2015 Apr;20(2):148-56
references: 24902007
references: Ann Pharmacother. 2014 Dec;48(12):1620-8
references: 25204465
references: J Drug Assess. 2014 Jan 16;3(1):10-9
references: 27536449
references: Br J Psychiatry. 1979 Apr;134:382-9
references: 444788
references: Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:89-95
references: 8923116